<DOC>
	<DOC>NCT00357825</DOC>
	<brief_summary>The purpose of this study is to assess the safety and effectiveness of [S,S]-Reboxetine in patients with fibromyalgia.</brief_summary>
	<brief_title>A Trial Assessing The Effectiveness and Safety of [S,S]-Reboxetine in Patients With Fibromyalgia</brief_title>
	<detailed_description />
	<mesh_term>Fibromyalgia</mesh_term>
	<mesh_term>Reboxetine</mesh_term>
	<criteria>At screening patients must meet the ACR criteria for fibromyalgia (i.e. widespread pain for at least 3 months, and pain in at least 11 of 18 specific tender point sites). At screening and randomization, patients must have a score of &gt;/=40mm on the Visual Analog Scale (VAS) of the ShortFormMcGill Pain Questionnaire (SFMPQ). Patients with other severe pain (e.g. DPN and PHN) that may confound assessment or selfevaluation of the pain associated with fibromyalgia. Patients with severe hepatic impairment.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2013</verification_date>
</DOC>